Literature DB >> 3260944

Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase.

Y Levy1, M S Hershfield, C Fernandez-Mejia, S H Polmar, D Scudiery, M Berger, R U Sorensen.   

Abstract

We report a 5-year-old girl with adenosine deaminase (ADA) deficiency who was asymptomatic during the first years of life. At 3 years of age, she developed chronic and recurrent sinopulmonary infections, and at 4 1/2 years of age she had one major infection with Streptococcus pneumoniae (bacteremia and septic arthritis of the hip). Immunologic evaluation at 5 years of age revealed persistent lymphopenia, decreased helper-suppressor T cell ratios, and low proliferative responses to mitogens. The IgG, IgM, and IgA levels were normal; the IgG2 level was low normal or below normal. The patient had specific antibodies against toxoids and viral antigens but failed to produce antibodies against Haemophilus influenzae type b and pneumococcal polysaccharides. Although no symptoms of allergy were present, she had persistent eosinophilia and elevated IgE levels. The patient had 0.6% of normal ADA activity in erythrocytes and approximately 1% of normal ADA activity in peripheral blood mononuclear cells. Beginning at 6 years of age, she was treated with weekly injections of polyethylene glycol-modified bovine ADA. This treatment was well tolerated and effectively reversed the biochemical consequence of ADA deficiency. Concomitantly, she improved clinically and her T lymphocyte numbers and blastogenic responses to mitogens in vitro became normal. The late onset of clinical symptoms and relatively benign clinical course in this patient emphasize the need to consider ADA deficiency in a broad spectrum of immunodeficient children.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260944     DOI: 10.1016/s0022-3476(88)80271-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  35 in total

Review 1.  Molecular pathophysiology of priapism: emerging targets.

Authors:  Uzoma A Anele; Belinda F Morrison; Arthur L Burnett
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

2.  Noninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors.

Authors:  Yashveer Singh; Dayuan Gao; Zichao Gu; Shike Li; Stanley Stein; Patrick J Sinko
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

Review 3.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  The genetic basis of pneumococcal and staphylococcal infections: inborn errors of human TLR and IL-1R immunity.

Authors:  Bertrand Boisson
Journal:  Hum Genet       Date:  2020-01-24       Impact factor: 4.132

5.  The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

Authors:  Christian Lubich; Peter Allacher; Maurus de la Rosa; Alexander Bauer; Thomas Prenninger; Frank Michael Horling; Jürgen Siekmann; Johannes Oldenburg; Friedrich Scheiflinger; Birgit Maria Reipert
Journal:  Pharm Res       Date:  2016-06-07       Impact factor: 4.200

6.  Adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency in common variable immunodeficiency.

Authors:  A Fleischman; M S Hershfield; S Toutain; H M Lederman; K E Sullivan; M B Fasano; J Greene; J A Winkelstein
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

7.  Pharmacokinetics and osteogenic potential of PEGylated NELL-1 in vivo after systemic administration.

Authors:  Jin Hee Kwak; Yulong Zhang; Juyoung Park; Eric Chen; Jia Shen; Chirag Chawan; Justine Tanjaya; Soonchul Lee; Xinli Zhang; Benjamin M Wu; Kang Ting; Chia Soo
Journal:  Biomaterials       Date:  2015-04-24       Impact factor: 12.479

8.  Correct splicing despite mutation of the invariant first nucleotide of a 5' splice site: a possible basis for disparate clinical phenotypes in siblings with adenosine deaminase deficiency.

Authors:  F X Arredondo-Vega; I Santisteban; S Kelly; C M Schlossman; D T Umetsu; M S Hershfield
Journal:  Am J Hum Genet       Date:  1994-05       Impact factor: 11.025

9.  Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype.

Authors:  I Santisteban; F X Arredondo-Vega; S Kelly; A Mary; A Fischer; D S Hummell; A Lawton; R U Sorensen; E R Stiehm; L Uribe
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).

Authors:  Claire Booth; H Bobby Gaspar
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.